文献速递瓣膜病与结构性心脏病

设计生物相容性原位组织工程心脏瓣膜:JACC本周综述

Designing Biocompatible Tissue Engineered Heart Valves In Situ: JACC Review Topic of the Week.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该综述指出瓣膜性心脏病全球高发,组织工程心脏瓣膜(TEHVs)有望作为终身替代物克服生物瓣与机械瓣局限。原位TEHVs通过生物指导性支架引导自体瓣膜生成、修复与重塑,但临床转化受限于TEHV与宿主相互作用的不可预测性和患者特异性。作者提出以原生瓣膜环境主动指导设计参数并设定功能评估基准的生物相容性TEHV开发与临床转化框架。

要点

  • 原位TEHVs旨在作为生物指导性支架引导自体瓣膜生长、修复与重塑。
  • 临床转化挑战主要在于TEHV与宿主相互作用的不可预测性和患者特异性。
  • 提出以原生瓣膜环境指导设计参数并设定功能评估基准的转化框架。

核心结论

  • 提出生物相容性TEHV的开发与临床转化框架,强调原生瓣膜环境主动指导设计参数并设定功能评估基准。

研究设计与样本

  • JACC综述,未报告系统检索范围与样本量。

主要发现

  • TEHVs有望作为终身瓣膜替代物克服生物瓣与机械瓣的局限。
  • 原位TEHVs通过生物指导性支架引导自体瓣膜在患者体内生长、修复与重塑。
  • 原位TEHVs临床转化挑战主要源于TEHV与宿主相互作用的不可预测性和患者特异性。

临床怎么用

  • TEHV设计应以原生瓣膜环境为依据确定设计参数并设定功能评估基准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Valvular heart disease is a globally prevalent cause of morbidity and mortality, with both congenital and acquired clinical presentations. Tissue engineered heart valves (TEHVs) have the potential to radically shift the treatment landscape for valvular disease by functioning as life-long valve replacements that overcome the current limitations of bioprosthetic and mechanical valves. TEHVs are envisioned to meet these goals by functioning as bioinstructive scaffolds that guide the in situ generation of autologous valves capable of growth, repair, and remodeling within the patient. Despite their promise, clinical translation of in situ TEHVs has proven challenging largely because of the unpredictable and patient-specific nature of the TEHV and host interaction following implantation. In light of this challenge, we propose a framework for the development and clinical translation of biocompatible TEHVs, wherein the native valvular environment actively informs the valve's design parameters and sets the benchmarks by which it is functionally evaluated.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Cordoves EM, Vunjak-Novakovic G, Kalfa DM, et al. Designing Biocompatible Tissue Engineered Heart Valves In Situ: JACC Review Topic of the Week. J Am Coll Cardiol. 2023. PMID: 36889879. doi:10.1016/j.jacc.2022.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。